Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291391 | 0.83 | PDE1B (0.47) | PDE1BGRM2JAK2JAK1GRM5 | |
| SCHEMBL20037928 | 0.82 | PDE1B (0.46) | PDE1BGRM2JAK2JAK1GRM5 | |
| SCHEMBL18291608 | 0.82 | PDE1B (0.44) | PDE1BGRM2JAK2JAK1GRM5 | |
| SCHEMBL20037606 | 0.81 | PDE1B (0.46) | PDE1BGRM2JAK2JAK1GRM5 | |
| SCHEMBL2739651 | 0.78 | HRH3 (0.51) | ALDH1A1LMNAMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL20249173 | 0.74 | HRH3 (0.49) | PDE1BALDH1A1LMNAMAPTKCNJ1 | |
| SCHEMBL20249525 | 0.73 | ALDH1A1 (0.36) | CCR9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL6132960 | 0.73 | JAK2 (0.44) | PDE1BGRM2JAK2JAK1ALDH1A1 | |
| SCHEMBL16852703 | 0.72 | CYP3A4 (0.36) | PDE1BGRM2JAK2JAK1ALDH1A1 | |
| SCHEMBL20249207 | 0.72 | CYP11B2 (0.40) | GRM2JAK2CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PDE1B 1496/4885GRM2 3074/4885JAK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.